sofosbuvir/velpatasvir/voxilaprevir

sofosbuvir/velpatasvir/voxilaprevir is a topic covered in the Davis's Drug Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

General

Genetic Implications: Genetic Implications

Pronunciation:
soe-fos-bue-vir/vel-pat-as-vir/vox-i-la-pre-vir

Trade Name(s)

  • Vosevi

Ther. Class.
antivirals

Pharm. Class.
NS5A inhibitors
NS5B inhibitors
protease inhibitors

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - sofosbuvir/velpatasvir/voxilaprevir ID - 110523 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir PB - F.A. Davis Company ET - 16 DB - Pediatrics Central DP - Unbound Medicine ER -